Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

FDA warns consumers about potential health risks of two natural dietary supplements

The U.S. Food and Drug Administration today issued a new warning to consumers about the potential health risks of two products marketed as natural dietary supplements for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions.

22 Aug 2012

Study on sea lamprey may indicate how potentially deleterious genes can be controlled

Research on a unique vertebrate called the sea lamprey shows that more than a thousand genes are shed during its early development.

22 Aug 2012

FDA extends action date for Pfizer’s tofacitinib NDA review

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).

22 Aug 2012

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is being supported by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health.

22 Aug 2012

GM-CSF depletion suppresses pain in people with arthritis-related conditions

The research relates to a family of molecules firstly discovered in Melbourne that applied to blood cell development. One of these, granulocyte macrophage colony-stimulating factor or GM-CSF, acts as a messenger between cells acting at a site of inflammation.

22 Aug 2012

Stem-cell therapy holds promise for postinjury arthritis prevention

A novel stem-cell treatment may hold the key to treating osteoarthritis triggered by joint injury, suggest results from an animal study.

21 Aug 2012

New silicon chips help identify patients with lupus

Researchers at the Stanford University School of Medicine and Intel Corp. have collaborated to synthesize and study a grid-like array of short pieces of a disease-associated protein on silicon chips normally used in computer microprocessors.

21 Aug 2012

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.

21 Aug 2012

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

21 Aug 2012

New attack on arthritis pain

A research team from the University of Melbourne is working on a new therapy that can potentially control the pain caused by diseases such as rheumatoid arthritis and osteoarthritis.

21 Aug 2012

Arthritis patients prioritize lifestyle intervention research

Most patients believe that research into joint pain should focus on self-management and lifestyle modifications, suggests a UK survey of older individuals with self-reported joint pain.

20 Aug 2012

Heart-healthy chocolate lowers blood pressure

Results from a systematic review and meta-analysis suggest that regular consumption of flavanol-rich cocoa powder or chocolate reduces blood pressure by a small but significant amount.

20 Aug 2012

Happtique introduces mRx solution for electronically prescribing medical apps

Happtique, a mobile health application store and total app management solution, today announced the commencement of its pilot program of mRx, Happtique's patent-pending solution that enables physicians and other health practitioners to electronically prescribe medical, health, and fitness apps to their patients.

20 Aug 2012

NYU Langone's Hospital for Joint Diseases achieves Magnet recognition by ANCC

NYU Langone Medical Center's Hospital for Joint Diseases (HJD) has achieved Magnet recognition by the American Nurses Credentialing Center (ANCC), the international accrediting body that recognizes healthcare organizations focused on nursing excellence.

18 Aug 2012

'Yoga for Healthy Lower Backs' likely to be cost effective for both NHS and wider society

Specialised group yoga classes could provide a cost-effective way of treating patients with chronic or recurrent low back pain, according to the UK's largest ever study of the benefits of yoga.

17 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night’s sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).

16 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine.

16 Aug 2012

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

The American Pain Society (APS) announced today it is accepting applications for research grants from the newly established Sharon S. Keller Chronic Pain Research Program.

16 Aug 2012

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

FDA warns consumers about potential health risks of two natural dietary supplements

Study on sea lamprey may indicate how potentially deleterious genes can be controlled

FDA extends action date for Pfizer’s tofacitinib NDA review

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

GM-CSF depletion suppresses pain in people with arthritis-related conditions

Stem-cell therapy holds promise for postinjury arthritis prevention

New silicon chips help identify patients with lupus

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

New attack on arthritis pain

Arthritis patients prioritize lifestyle intervention research

Heart-healthy chocolate lowers blood pressure

Happtique introduces mRx solution for electronically prescribing medical apps

NYU Langone's Hospital for Joint Diseases achieves Magnet recognition by ANCC

'Yoga for Healthy Lower Backs' likely to be cost effective for both NHS and wider society

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in